Avadel Pharmaceuticals plc (AVDL) Financial Ratios
29 years of historical data (1996–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 56.74
30Y Low3.5·High56.7
P/FCF
N/A
—
5yr avg: N/A
30Y Low6.4·High50.7
P/B Ratio
↑
27.88
↑+221% vs avg
5yr avg: 8.69
30Y Low1.3·High34.6
ROE
↓
-60.4%
↓+72% vs avg
5yr avg: -215.4%
30Y Low-481%·High106%
Debt/EBITDA
N/A
—
5yr avg: 17.39
30Y Low0.0·High17.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AVDL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Avadel Pharmaceuticals plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $1000M | $1.1B | $430M | $473M | $367M | $282M | $96M | $342M | $429M | $533M |
| Enterprise Value | $2.1B | $950M | $1.1B | $487M | $567M | $426M | $397M | $203M | $326M | $390M | $469M |
| P/E Ratio → | -42.43 | — | — | — | — | 51.38 | — | — | 5.09 | — | 13.13 |
| P/S Ratio | 12.44 | 5.91 | 40.48 | — | — | 16.43 | 4.77 | 0.93 | 1.98 | 2.85 | 3.07 |
| P/B Ratio | 27.88 | 13.54 | 12.90 | — | 6.04 | 2.26 | — | 34.64 | 4.05 | 10.19 | 7.85 |
| P/FCF | — | — | — | — | — | — | — | — | — | 24.21 | 6.44 |
| P/OCF | — | — | — | — | — | — | — | — | 20.55 | 22.67 | 6.32 |
P/E links to full P/E history page with 30-year chart
AVDL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.62 | 39.46 | — | — | 19.07 | 6.71 | 1.96 | 1.89 | 2.60 | 2.71 |
| EV / EBITDA | — | — | — | — | — | 56.74 | — | — | 3.50 | 40.97 | 5.54 |
| EV / EBIT | — | — | — | — | — | 53.82 | — | — | 5.35 | — | 6.03 |
| EV / FCF | — | — | — | — | — | — | — | — | — | 22.04 | 5.67 |
AVDL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Avadel Pharmaceuticals plc earns an operating margin of -25.1%. Operating margins have expanded from -493.0% to -25.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -60.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.0% | 91.0% | 97.0% | — | — | 74.3% | 79.5% | 83.0% | 90.6% | 91.2% | 93.7% |
| Operating Margin | -25.1% | -25.1% | -493.0% | — | — | 26.0% | -40.7% | -101.6% | 51.1% | -3.3% | 41.2% |
| Net Profit Margin | -28.9% | -28.9% | -573.2% | — | — | 31.5% | -56.1% | -92.3% | 38.9% | -27.5% | 23.5% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.4% | -60.4% | -481.4% | -481.5% | -64.3% | 10.6% | — | -218.2% | 106.2% | -75.1% | 87.7% |
| ROA | -29.7% | -29.7% | -107.8% | -72.3% | -27.7% | 3.0% | -19.4% | -43.1% | 27.0% | -17.9% | 20.9% |
| ROIC | -76.3% | -76.3% | -217.4% | -70.9% | -32.6% | 2.8% | -18.6% | -88.6% | 184.1% | -98.1% | 99.7% |
| ROCE | -34.9% | -34.9% | -134.6% | -65.0% | -32.7% | 2.8% | -18.0% | -66.0% | 50.6% | -2.8% | 53.0% |
AVDL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $51M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.03 | — | 1.85 | 0.80 | — | 41.67 | 0.00 | 0.02 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | 17.39 | — | — | 0.00 | 0.09 | 0.01 |
| Net Debt / Equity | — | -0.67 | -0.33 | — | 1.21 | 0.36 | — | 38.31 | -0.19 | -0.91 | -0.94 |
| Net Debt / EBITDA | — | — | — | — | — | 7.84 | — | — | -0.17 | -4.03 | -0.76 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -2.17 | -0.77 |
| Interest Coverage | -3.91 | -3.91 | -13.94 | -7.99 | -8.60 | 0.45 | -1.93 | -9.88 | 83.94 | -5.16 | 11.34 |
Net cash position: cash ($51M) exceeds total debt ($2M)
AVDL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Avadel Pharmaceuticals plc's current ratio of 2.75x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.33x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 1.81x to 2.75x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.75 | 2.75 | 3.64 | 1.81 | 9.17 | 17.44 | 2.29 | 3.25 | 1.44 | 2.90 | 3.41 |
| Quick Ratio | 2.33 | 2.33 | 3.36 | 1.81 | 9.17 | 17.44 | 2.19 | 3.13 | 1.37 | 2.85 | 3.32 |
| Cash Ratio | 1.51 | 1.51 | 2.85 | 1.73 | 7.49 | 14.65 | 1.78 | 2.60 | 1.09 | 2.47 | 2.97 |
| Asset Turnover | — | 1.03 | 0.17 | — | — | 0.07 | 0.39 | 0.54 | 0.69 | 0.61 | 0.81 |
| Inventory Turnover | 0.75 | 0.75 | 0.08 | — | — | — | 3.40 | 3.67 | 2.65 | 4.07 | 2.63 |
| Days Sales Outstanding | — | 73.59 | 157.98 | — | — | 633.81 | 73.81 | 49.17 | 34.88 | 43.34 | 15.78 |
AVDL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Avadel Pharmaceuticals plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 1.9% | — | — | 19.6% | — | 7.6% |
| FCF Yield | — | — | — | — | — | — | — | — | — | 4.1% | 15.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 28.7% | 6.5% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 28.7% | 6.5% | 0.0% | 0.0% |
| Shares Outstanding | — | $95M | $80M | $60M | $59M | $55M | $37M | $37M | $42M | $41M | $44M |
Peer Comparison
Compare AVDL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AVDLYou | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 JAZZ | $14B | -39.1 | 24.0 | 11.1 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 AXSM | $11B | -60.5 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PGNY | $2B | 28.8 | 16.0 | 8.0 | 23.6% | 6.6% | 12.5% | 18.1% | 0.3 |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 COLL | $1B | 21.1 | 4.5 | 3.6 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See AVDL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVDL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVDL vs JAZZ
Side-by-side business, growth, and profitability comparison vs Jazz Pharmaceuticals plc.
Start ComparisonAVDL — Frequently Asked Questions
Quick answers to the most common questions about buying AVDL stock.
What is Avadel Pharmaceuticals plc's P/E ratio?
Avadel Pharmaceuticals plc's current P/E ratio is -42.4x. The historical average is 26.1x.
What is Avadel Pharmaceuticals plc's ROE?
Avadel Pharmaceuticals plc's return on equity (ROE) is -60.4%. The historical average is -77.0%.
Is AVDL stock overvalued?
Based on historical data, Avadel Pharmaceuticals plc is trading at a P/E of -42.4x. Compare with industry peers and growth rates for a complete picture.
What are Avadel Pharmaceuticals plc's profit margins?
Avadel Pharmaceuticals plc has 91.0% gross margin and -25.1% operating margin.